The Effect of Bevacizumab-Related Hypertension on the Prognosis of Patients with Colorectal Cancer and Non-Small Cell Lung Cancer

被引：0
|
作者：
Pan, Juhua [1 ]
Zheng, Liangda [2 ]
Liu, Binghui [1 ]
You, Shuqing [1 ]
Zheng, Weizhi [1 ]
机构：
[1] Taizhou First Peoples Hosp, Dept Pathol, Taizhou 318020, Zhejiang, Peoples R China
[2] Taizhou First Peoples Hosp, Dept Hematol, Taizhou 318020, Zhejiang, Peoples R China
来源：
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2022年 / 84卷
关键词：
Bevacizumab; hypertension; colorectal cancer; non-small cell lung cancer; prognosis;
D O I：
10.36468/pharmaceutical-sciences.spl.448
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
To study and analyze the effect of bevacizumab-related hypertension on the prognosis of patients with colorectal cancer and non-small cell lung cancer. The study randomly selected 100 colorectal cancer patients and 100 non-small cell lung cancer patients who received therapy in our hospital from October 2019 to October 2021. Among them, adopted intervention for 100 colorectal cancer patients with bevacizumab combined with cytotoxic drug chemotherapy and adopted intervention for 100 non-small cell lung cancer patients with bevacizumab combined with standard chemotherapy. Bevacizumab treatment has better therapeutic effect of hypertension on colorectal cancer patients than non-small cell lung cancer patients. Compared with colorectal cancer patients who received bevacizumab treatment, non-small cell lung cancer patients under bevacizumab treatment caused more adverse reactions. Among 100 colorectal cancer patients, the number of patients with bevacizumab-related hypertension in grade 1, grade 2 and grade 3 were 45, 12 and 23 respectively. Among 100 non-small cell lung cancer patients, the number of patients with bevacizumab-related hypertension in grade 1, grade 2 and grade 3 were 44, 25 and 20 respectively. Bevacizumab-related hypertension can improve the prognosis and efficacy of colorectal cancer and non-small cell lung cancer patients.
引用
收藏
页码：21 / 24
页数：4
相关论文
共 50 条
  • [21] Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer
    Morita, Sachi
    Uehara, Keisuke
    Nakayama, Goro
    Shibata, Takashi
    Oguri, Tomoyo
    Inada-Inoue, Megumi
    Shimokata, Tomoya
    Sugishita, Mihoko
    Mitsuma, Ayako
    Ando, Yuichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 405 - 411
  • [22] Bevacizumab and non-small cell lung cancer: a new step?
    Perol, M.
    Arpin, D.
    REVUE DES MALADIES RESPIRATOIRES, 2009, 26 (02) : 125 - 138
  • [23] Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients
    Muto, Satoshi
    Takagi, Hironori
    Owada, Yuki
    Inoue, Takuya
    Watanabe, Yuzuru
    Yamaura, Takumi
    Fukuhara, Mitsuro
    Okabe, Naoyuki
    Matsumura, Yuki
    Hasegawa, Takeo
    Osugi, Jun
    Hoshino, Mika
    Higuchi, Mitsunori
    Shio, Yutaka
    Suzuki, Hiroyuki
    ANTICANCER RESEARCH, 2017, 37 (06) : 3169 - 3174
  • [24] Expression of Chemerin Correlates With a Favorable Prognosis in Patients With Non-Small Cell Lung Cancer
    Zhao, Shen
    Li, Chao
    Ye, Yun-bin
    Peng, Feng
    Chen, Qiang
    LABMEDICINE, 2011, 42 (09): : 553 - 557
  • [25] THE COMBINATION CHEMOTHERAPY OF GEMCITABINE, CARBOPLATIN AND BEVACIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Kim, Bong Seog
    Ahn, Young Mi
    Lee, Moon Hyung
    Suh, Kang Heum
    Nam, Seung-Hyun
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1158 - S1158
  • [26] The Use of Bevacizumab in Non-Small Cell Lung Cancer: An Update
    Lauro, Salvatore
    Onesti, Concetta Elisa
    Righini, Riccardo
    Marchetti, Paolo
    ANTICANCER RESEARCH, 2014, 34 (04) : 1537 - 1545
  • [27] Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
    Boutsikou, Eftimia
    Kontakiotis, Theodoros
    Zarogoulidis, Paul
    Darwiche, Kaid
    Eleptheriadou, Ellada
    Porpodis, Konstantinos
    Galaktidou, Grammati
    Sakkas, Leonidas
    Hohenforst-Schmidt, Wolfgang
    Tsakiridis, Kosmas
    Karaiskos, Theodoros
    Zarogoulidis, Konstantinos
    ONCOTARGETS AND THERAPY, 2013, 6 : 125 - 134
  • [28] Clinical Efficacy of Bevacizumab Concomitant with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer
    Zhang, Yu-Mei
    Li, Yong-Qiang
    Liu, Zhi-Hui
    Liao, Xiao-Li
    Liang, Rong
    Lin, Yan
    Yuan, Chun-Ling
    Liao, Si-Na
    Liang, Chao-Yong
    Li, Qian
    Li, Le-Qun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (08) : 3447 - 3450
  • [29] Bevacizumab: Its Place in the Treatment of Advanced Non-small Cell Lung Cancer
    Agarwal, V.
    Prasad, R.
    Butt, M.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 715 - 725
  • [30] Bowel perforation in non-small cell lung cancer after bevacizumab therapy
    Schellhaas, Elisabeth
    Loddenkemper, Christoph
    Schmittel, Alexander
    Buhr, Heinz-J.
    Pohlen, Uwe
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 184 - 187
12345